Trial Profile
Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Veliparib (Primary)
- Indications Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- 06 Apr 2023 Planned End Date changed from 31 Dec 2023 to 1 Jul 2024.
- 06 Apr 2023 Planned primary completion date changed from 31 Dec 2023 to 1 Jul 2024.
- 06 Apr 2023 Status changed from recruiting to active, no longer recruiting.